Kit Inhibitors

KIT Inhibitors is a class of tyrosine kinase inhibitors that specifically target the KIT receptor tyrosine kinase, thereby blocking its aberrant signaling in oncogenic pathways.

195

Publications

19.4K

Citations

1.7K

Authors

523

Institutions

Publications per year

2017–2026

51

Variants

Kit Tyrosine Kinase Inhibitors

Authors

1.7K

  1. MC
    Michael C. Heinrich

    Oregon Health & Science University, United States

    15 publications · 8.3K citations

    14

    h-index

  2. JA
    Jonathan A. Fletcher

    Brigham and Women's Hospital, United States

    13 publications · 7.6K citations

    13

    h-index

  3. GD
    George D. Demetri

    Dana-Farber Cancer Institute, United States

    9 publications · 7.6K citations

    9

    h-index

  4. PS
    Patrick Schöffski

    KU Leuven, Belgium

    8 publications · 495 citations

    8

    h-index

  5. MD
    Maria Dêbiec‐Rychter

    KU Leuven, Belgium

    7 publications · 490 citations

    7

    h-index

1–5 of 1.7K

Venues

  1. Journal of Clinical Oncology

    19 publications · 923 citations

    13

    h-index

  2. Clinical Cancer Research

    12 publications · 967 citations

    12

    h-index

  3. Journal of Medicinal Chemistry

    11 publications · 447 citations

    11

    h-index

  4. PubMed

    Repository · 11 publications · 1.5K citations

    11

    h-index

  5. Cancer Research

    11 publications · 832 citations

    11

    h-index

1–5